Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - read this article along with other careers information, tips and advice on BioSpace

Related Keywords

Finland ,United States ,America ,American ,John Mullaly ,Chris Giordano ,Thenappan ,Heart Failure Society Of America ,Lifesci Advisors ,Nasdaq ,Orion Corporation ,Pulmonary Hypertension Program ,University Of Minnesota ,Tenax Therapeutics Inc ,Hemodynamic Evaluation ,Heart Failure Society ,Scientific Sessions ,Chronic Intravenous ,Oral Levosimendan Is Safe ,Pulmonary Hypertension ,Heart Failure ,Preserved Ejection ,Section Leader ,Kansas City Cardiomyopathy Questionnaire ,Stuart Rich ,Chief Medical Officer ,Tenax Therapeutics ,Therapeutic Chief Executive Officer ,North American ,Preserved Ejection Fraction ,Tenax Therapeutic Phase ,Tenax Therapeutic ,Sci Advisors ,Resume ,Careers ,Ositive Data Presented At Hfsa Annual Meeting Demonstrate Effects Of Oral Levosimendan In Patients With Pulmonary Hypertension And Heart Failure Preserved Ejection Fraction Ph Hfpef ,Iospace ,Advice ,